Fundz

Annexon, Inc. Secures $75 Million in Public Offering

PUBLIC · ANNXNov 14, 2025

Amount Raised

$75 Million

Round Type

Post-IPO Equity

BrisbaneBiotechnology

Description

On November 12, 2025, Annexon, Inc completed a public offering of common stock and pre-funded warrants. The company issued and sold 25,096,153 shares at $2.60 per share and pre-funded warrants for an additional 3,750,000 shares at $2.599 each. This funding event is aimed at supporting the company's operational and development initiatives. The offering was facilitated by leading underwriters including Goldman Sachs & Co LLC, TD Securities (USA) LLC, and Wells Fargo Securities, LLC.

Quick answer

Annexon raised $75 Million in a Post-IPO Equity round, dated November 14, 2025. Annexon is based in Brisbane, California, United States.

How much did Annexon raise?
Annexon raised $75 Million in a Post-IPO Equity round on November 14, 2025.
What does Annexon do?
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders..
Where is Annexon based and how big is it?
Annexon is based in Brisbane, California, United States. Fundz records about 119 employees.
Who are the decision-makers at Annexon?
Fundz holds 1 contact at Annexon, including the Executive Officer. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Annexon that raised within 45 days of this round, from Fundz verified event records.

  • Dermata Therapeutics raised $4.1M on December 29, 2025.
  • CASI Pharmaceuticals raised $5M on December 27, 2025.
  • GPN Vaccines raised $3.5M on December 24, 2025.
  • SI Group raised $150M (Funding Round) on December 24, 2025.
  • DP Technology raised $114M (Series C) on December 24, 2025.
  • Holobiome raised $10M on December 24, 2025.

Who to call at Annexon, and when

A new round usually means Annexon is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Annexon raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Annexon, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Annexon. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Annexon

Location

1400 Sierra Point Parkway

Brisbane, California, United States

About

Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company’s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Annexon raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsMichael O., Executive OfficerSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Annexon's next move

See what Strategic adds

Annexon raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.